Biogen Inc.

4 days ago · benzinga.com

Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.

4 days ago · globenewswire.com

Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration Presentations across Biogen's Alzheimer's disease portfolio reflect its continued commitment to advancing innovation in Alzheimer's disease, from long-term treatment outcomes and real-world evidence to investigational approaches targeting core disease pathologies, including amyloid and tau CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts.

4 days ago · marketbeat.com

Biogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said the company remains on track to return to top-line growth in 2026 and raised the lower end of its full-year non-GAAP diluted earnings-per-share guidance.

4 days ago · seekingalpha.com

Biogen Inc. ( BIIB ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - Executive VP & Head of Development Robin Kramer - Executive VP & CFO Alisha Alaimo - President & Head of North America Conference Call Participants Philip Nadeau - TD Cowen, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Michael Yee - UBS Investment Bank, Research Division Alexandria Hammond - Wolfe Research, LLC Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Evan Seigerman - BMO Capital Markets Equity Research Geoffrey Meacham - Citigroup Inc., Research Division David Amsellem - Piper Sandler & Co., Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Lin Tsai - Jefferies LLC, Research Division Marc Goodman - Leerink Partners LLC, Research Division Presentation Operator Good morning. My name is Cynthia, and I will be your conference operator today.

5 days ago · zacks.com

Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.

5 days ago · zacks.com

We have a solid slate of reports today, both of the earnings variety and regarding economic growth.

5 days ago · zacks.com

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

5 days ago · zacks.com

Biogen Inc. (BIIB) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $4.81 per share a year ago.

5 days ago · wsj.com

The biotechnology company said the swing to a loss was primarily due to transaction-related charges.

7 days ago · zacks.com

Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.